Modalis Therapeutics Corporation announced it will regain full development and commercial rights to MDL-201 and MDL-202 from Astellas Pharma Inc. It also reveals that target indications for the products are Duchene Muscular Dystrophy (DMD) and Myotonic Dystrophy type 1 (DM1), respectively. Modalis is also announcing a sharpened strategic focus, to prioritize its investments in the most promising programs: MDL-101, the lead program in its pipeline which has completed preIND and is moving forward to the clinic for LAMA2-CMD, and MDL-202 for DM1. This matter shall have a minor impact on cost compared with that of the whole R&D for the fiscal year ending December 31, 2023, and the following years.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
77 JPY | 0.00% | -1.28% | -37.90% |
Apr. 15 | Modalis Therapeutics to See Reduced Expenses of 250 to 350 Million After Cutting Jobs | MT |
Feb. 23 | Modalis Therapeutics to Reduce Stated Capital and Capital Reserves | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,506 JPY | +3.51% | +1.72% | 17.15B | ||
77 JPY | 0.00% | -1.28% | 16.73M | ||
1st Jan change | Capi. | |
---|---|---|
-37.90% | 16.73M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.67% | 22.15B | |
-17.37% | 21.02B | |
-8.47% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- 4883 Stock
- News Modalis Therapeutics Corporation
- Modalis Therapeutics Corporation to Regain Full Rights to MDL-201 and MDL-202 from Astellas Pharma Inc